Pasar al contenido principal

Investigación y educación

Enviado por remote_content el

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y Educación

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Candida auris: A Latent Threat to Critically Ill Patients with Coronavirus Disease 2019. Clin Infect Dis.

Noviembre 2, 2021

Leer más

Enfermedades infecciosas

Consensus recommendations based on evidence for abdominal sepsis in the pediatric and adult population of colombia. Infectio,

Julio 30, 2022

Leer más

Enfermedades infecciosas

Latin America: Situation and preparedness facing the multi-country human monkeypox outbreak. Lancet Reg Health Am.

Julio 6, 2022

Leer más